INDEZA (ENZALUTAMIDE) is indicated for prostate cancer.
Indicated for the treatment of castration-resistant prostate cancer (CRPC) and metastatic castration-resistant prostate cancer (mCSPC).
Enzalutamide is an inhibitor for androgen receptor signaling.
Enzalutamide is a triple action drug.
Enzalutamide slows down the binding of androgen to its receptor by inhibiting AR-T binding.
Enzalutamide acts on cancer cells, inhibiting their growth, and blocking activation
changes caused by AR-T binding.
Enzalutamide inhibits intra-nuclear AR-T translocation and DNA transcription, which leads to the death of tumor cells.